Working inthe Centauri lab

Revolutionising immunotherapy for the most vulnerable patients through our novel Alphamer® technology.

Centauri Therapeutics is an immunotherapy company currently focused on infectious diseases and oncology. Centauri’s approach to treating infectious diseases rests upon proprietary Alphamer® technology. All projects harness a powerful and clinically validated immune mechanism which redirects naturally existing antibodies to treat life-threatening diseases.

Latest News and Articles

Centauri Therapeutics awarded £1M grant under new PACE programme to advance immunotherapy platform in anti-infectives

November 25, 2024

Centauri is excited to announce that we have been selected…

Read More

Centauri Therapeutics closes £24m Series A investment round

January 26, 2022

Centauri Therapeutics is delighted to announce new investment of £24m…

Read More

Centauri awarded follow-on CARB-X grant

February 22, 2022

Centauri Therapeutics Limited, an immunotherapy company focused on the treatment…

Read More